Navigation Links
Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
Date:7/9/2008

SOUTH SAN FRANCISCO, Calif., July 9 /PRNewswire/ -- Portola Pharmaceuticals, Inc., a privately-held biotechnology company focused on the discovery and development of novel therapeutics for cardiovascular and inflammatory diseases, announced today that is has raised $60 million in a preferred stock financing. Proceeds will be used primarily to advance Portola's two lead antithrombotic clinical candidates, betrixaban and PRT060128, which the company is developing as best-in-class compounds to replace existing standards of care. In addition, funds will be used to develop the company's pre-clinical pipeline including its novel Factor Xa inhibitor antidote, which has the potential to expand the use of anticoagulants. New investors, including D.E. Shaw group, Adage Capital Management, BBT Capital Management/Apothecary Capital, Janus Capital Group and PAC-LINK BioVentures, joined the company's existing investors to complete the round.

"Raising funds from this outstanding group of investors in this challenging market validates the potential value of our novel product candidates for thrombosis, one of the world's largest markets," said Charles Homcy, M.D., president and chief executive officer of Portola. "These funds will also help us advance a novel Factor Xa inhibitor antidote and our Syk and JAK inhibitor program, which further diversify the company's pipeline and may offer opportunities for accelerated product development."

Two Clinical Candidates Address Global Thrombosis Market

Portola is advancing two differentiated drug candidates that address the global, multi-billion dollar antithrombotic market where existing drugs, such as enoxaparin (Lovenox(R)), clopidogrel (Plavix(R)) and warfarin (Coumadin(R)), have well known limitations.

Betrixaban, the company's first Phase 2 drug candidate, is an oral Factor Xa inhibitor. Factor Xa is a validated target for which there are approved drugs on the market, and inhibiting its activity is bel
'/>"/>

SOURCE Portola Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pulmo BioTech Inc. Completes Bio-Distribution Studies
2. Isolagen Completes Pivotal Efficacy Portion of Phase III Studies of Isolagen Therapy(TM) for Wrinkles
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
5. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
6. Pharmaxis Long-Term Safety Study of Bronchitol Completes
7. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
8. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
9. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
10. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
11. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014 Synthetic ... technology partnership with global bioengineering leader DNA2.0, ... for quick-to-market products. The integration ... machine learning optimization technologies, such as ProteinGPS™ ... process of engineering proteins in the Pareto ...
(Date:7/14/2014)... , July 14, 2014 BioAdaptives, Inc. ... , Chairman has assumed the roles of President and ... of Ferris Holding, Inc., the company that licensed its ... and its financial supporter. "Mr. ... our early transition as a privately held entity to ...
(Date:7/13/2014)... 13, 2014 Auf ... Tokio veranstalteten F&E-Tagung meldete Astellas ... Neuausrichtung seines Forschungsrahmenprogramms. Die Tagung bot Astellas ... fortgeschrittenen klinischen Programme und die Konzernstrategie des ... bestand darin, aktuelle Meldungen zu den Astellas-Initiativen ...
Breaking Medicine Technology:Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 2Pareto Biotechnologies Announces Technology Partnership With DNA2.0, Inc. 3BioAdaptives Prepares for Next Step 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4
... Calif., Nov. 14 VNUS(R) Medical,Technologies, Inc. (Nasdaq: ... devices,for the minimally invasive treatment of venous reflux ... using the VNUS,ClosureFAST catheter were presented today at ... VNUS ClosureFAST(TM) catheter is an endovenous,radiofrequency (RF) ablation ...
... Multi-national study compared FORTEO and the currently ... the treatment of Glucocorticoid-Induced Osteoporosis, INDIANAPOLIS, ... The New England Journal of Medicine, showed ... 1-34, teriparatide [rDNA,origin] injection) significantly increased lumbar ...
Cached Medicine Technology:Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium 2Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium 3FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 2FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 3FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 4FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 5FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis 6
(Date:7/14/2014)... 14, 2014 The Cabin Chiang Mai, ... new Alumni Community website – a free ... help them maintain lifelong recovery wherever they live in ... clients the tools to help them maintain their recovery ... part of any reputable treatment programme. As a chronic ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 ... Protocol book review recently updated by Vkool.com, ... of a wide range of simple and ... endometriosis including:,     Increasing ... and dairy products ,     Increasing fiber ...
(Date:7/14/2014)... 2014 Reha Technology today announced ... portable and full-featured upper extremity robotic trainer that ... interactive games and challenges in a lightweight and ... , Armotion combines a variety of ... maximize the therapy effect for patients with severe ...
(Date:7/14/2014)... July 14, 2014 Love Digits LLC ... called Love Digits. The App brings ancient astrology to ... to quantify their compatibility using a five-star rating system. ... people can instantaneously test their compatibility for love and ... , The app’s five-star rating system generates a weighted ...
(Date:7/14/2014)... MT (PRWEB) July 14, 2014 New ... Women's Voices for the Earth examines toxic ... majority of women nationwide, including specific chemicals that may ... as additives and fragrances that may put women’s health ... science and research, Alexandra Scranton , the potential ...
Breaking Medicine News(10 mins):Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:Endometriosis Bible and Violet Protocol Book Review Exposes Zoe Brown's Endometriosis Treatment Guide – Vkool.com 2Health News:Endometriosis Bible and Violet Protocol Book Review Exposes Zoe Brown's Endometriosis Treatment Guide – Vkool.com 3Health News:Reha Technology Launches the Armotion™, a Device for the Rehabilitation of the Upper Extremity 2Health News:Love Digits, Numerical Approach to Modern Love, Now Available on iTunes 2Health News:Love Digits, Numerical Approach to Modern Love, Now Available on iTunes 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 2Health News:New Patent Analysis Shows Toxic Risk From Tampons 3Health News:New Patent Analysis Shows Toxic Risk From Tampons 4Health News:New Patent Analysis Shows Toxic Risk From Tampons 5
... this country has nearly doubled in the past 20 years. ... therapists are charged with the task, but many are falling ... lack scientific rigor. This is in part because many of ... for-profit training centersare not grounded in science. A new ...
... , BOSTON, Oct. 2 Hess Corporation will present two $50,000 ... Foundation and the other to Children,s Hospital Boston,s Trauma Program -- ... Red Sox, home opening day. Aric Morrison, a Hess Retail regional ... , Hess Corporation promised to donate $500 for every home run ...
... award today for excellence in research, advancing oral health ... will receive the 2009 American Dental Association,s (ADA) Gold Medal ... formal presentation during a meeting of the ADA,s House ... once every three years, the award honors individuals who contribute ...
... highest honor on Kenneth L. Kalkwarf, D.D.S. at its 150th ... American Dental Association (ADA) will honor Kenneth L. Kalkwarf, D.D.S., ... Session and World Marketplace Exhibition in Honolulu. The Distinguished Service ... individual. , ADA President John S. Findley, D.D.S., ...
... 2 Beginning October 1st, The Peninsula Chicago will dedicate ... Month and several cancer research and education organizations. , "We ... cancer in some way and this is why we at ... Zec, general manager of The Peninsula Chicago. "In addition to ...
... 2 Pillar Capital is pleased to announce its acquisition ... to an order of the Bankruptcy Court for the District ... free and clear of claims. The Medico Labs business ... in 2000, manufactures and distributes private label and store brand ...
Cached Medicine News:Health News:Where's the science? The sorry state of psychotherapy 2Health News:Hess Home Run Campaign a Hit for Kids with Medical Needs 2Health News:Hess Home Run Campaign a Hit for Kids with Medical Needs 3Health News:ADA's 2009 Gold Medal Award Presentation Set for 150th Annual Session 2Health News:Dental Educator to Receive the ADA Distinguished Service Award 2Health News:Dental Educator to Receive the ADA Distinguished Service Award 3Health News:The Peninsula Chicago Gives Back During Breast Cancer Awareness Month 2Health News:Pillar Capital Announces Acquisition of Medico Labs' Assets 2
... Bird and Cronin, ... manufacturer of Patient Footwear, ... Patient Care Products. Our ... highest quality and available ...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... The Blue Line Wrist Control offers a ... wrist support for Carpal Tunnel Syndrome, tendinitis, ... the wrist. Careful design leaves fingers free ... wrist. Lightweight metal stay can be contoured ...
Combination Oppenheimer with Knuckle Bender - to dorsiflex wrist and flex MCP joints; includes two attachments to extend/flex distal finger joints....
Medicine Products: